Octagon Research Solutions Announces StartingPoint 4.0
Octagon Research Solutions, Inc., has released version 4.0 of its global submission document authoring template suite, StartingPoint.
StartingPoint 4.0 is designed to offer standardized templates and formatting functionality to those authoring the various components of a CTD (Common Technical Document) or eCTD (electronic Common Technical Document) regulatory submission. StartingPoint 4.0 offers new content templates, improved functionality and compliance with Windows 7.
New functionality includes:
* Enhanced error identification and management o
- Expanded list of errors highlighted by the Document Validation tool
- A new ‘Report Generation’ mode that enables the user to generate a comprehensive report of all errors found in the document.
- The addition of a ‘Replace All’ feature allowing replacement of all instances of erroneous style with one button push.
* Enhanced toolbar automation that addresses common challenges with table and footnote formatting
* Automated ‘Replace Styles’ functionality that allows the user to map each existing style in a document to a specified StartingPoint style.
* New and enhanced content templates reflecting recent changes in regulatory guidance including:
- 1.16 Proposed Risk Evaluation and Mitigation Strategies (REMS)
-1.16 Risk Evaluation and Mitigation Strategies (REMS) Supporting Document
-1.6.1 Meeting Request
-1.6.2 Pre-NDA Meeting Background Materials
“The Risk Evaluation and Mitigation Strategies (REMS) content template was added to this version of StartingPoint as a result of our agency interactions and is based on just released guidance from the FDA. We are seeing an increased emphasis on the REMS and felt it appropriate to include the content template to assist our clients in developing a framework for this critical document," stated John Lawrie, vice president, Process Consulting.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
